Vanguard Group Inc. Sells 71,326 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Vanguard Group Inc. decreased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 1.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 6,036,183 shares of the specialty pharmaceutical company's stock after selling 71,326 shares during the quarter. Vanguard Group Inc. owned approximately 9.98% of Jazz Pharmaceuticals worth $743,356,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. Cinctive Capital Management LP bought a new position in Jazz Pharmaceuticals during the third quarter worth about $14,277,000. Pacer Advisors Inc. lifted its position in shares of Jazz Pharmaceuticals by 5.5% during the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock worth $272,713,000 after acquiring an additional 115,102 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Jazz Pharmaceuticals by 135.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company's stock worth $19,394,000 after acquiring an additional 100,112 shares during the period. GW&K Investment Management LLC grew its position in shares of Jazz Pharmaceuticals by 26.6% in the fourth quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company's stock valued at $57,142,000 after purchasing an additional 97,589 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in Jazz Pharmaceuticals by 501.4% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 112,055 shares of the specialty pharmaceutical company's stock worth $13,800,000 after purchasing an additional 93,422 shares during the period. Hedge funds and other institutional investors own 89.14% of the company's stock.

Insider Activity

In other Jazz Pharmaceuticals news, CMO Robert Iannone sold 7,080 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the sale, the chief marketing officer now owns 82,024 shares in the company, valued at approximately $11,368,526.40. The trade was a 7.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Patricia Carr sold 1,140 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $137.81, for a total value of $157,103.40. Following the sale, the chief accounting officer now directly owns 7,012 shares of the company's stock, valued at approximately $966,323.72. This trade represents a 13.98 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 28,736 shares of company stock valued at $4,023,305. Corporate insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ traded down $5.62 on Thursday, reaching $120.82. 1,428,835 shares of the company's stock traded hands, compared to its average volume of 748,017. The stock has a market cap of $7.34 billion, a PE ratio of 17.02, a P/E/G ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $148.06. The stock has a 50-day simple moving average of $132.51 and a 200 day simple moving average of $122.91. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Analysts Set New Price Targets

Several brokerages have recently weighed in on JAZZ. HC Wainwright increased their price target on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a report on Monday, March 10th. Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Truist Financial boosted their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Royal Bank of Canada lowered their price objective on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 26th. Finally, Needham & Company LLC restated a "buy" rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Jazz Pharmaceuticals has an average rating of "Buy" and an average price target of $187.71.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.